Pfizer is on track to deliver 120 million doses of its two-dose regimen by the end of March, said John Young, Pfizer's chief business officer.
Pfizer is also prepared to provide a total of 300 million shots to the United States by the end of July and has raised global production expectations for 2021 to at least 2 billion doses, he said.
In his own prepared remarks, Moderna Inc President Stephen Hoge said the drugmaker plans to deliver 100 million doses of its two-dose shot by the end of March, and 300 million by the end of July.
console.log("BODY2. CatId is:"+catID);if(catID==120){console.log("BODY. YES for anyclip script");document.getElementsByClassName("divConnatix")[0].style.display ="none";var script = document.createElement('script'); script.src = 'https://player.anyclip.com/anyclip-widget/lre-widget/prod/v1/src/lre.js'; script.setAttribute('pubname','jpostcom'); script.setAttribute('widgetname','0011r00001lcD1i_12258'); document.getElementsByClassName('divAnyClip')[0].appendChild(script);}else if(catID!=69 && catID!=2){console.log("BODY. YES for vidazoo script");document.getElementsByClassName("divConnatix")[0].style.display ="none"; var script = document.createElement('script'); script.src = 'https://static.vidazoo.com/basev/vwpt.js'; script.setAttribute('data-widget-id','60fd6becf6393400049e6535'); document.getElementsByClassName('divVidazoo')[0].appendChild(script); }Johnson & Johnson believes it will be able to ship at least 20 million doses of its single-dose shot to the United States by the end of March after receiving US regulatory authorization and 100 million doses by mid-year 2021, said Vice President of Medical Affairs Richard Nettles.
The comments were prepared ahead of a US congressional hearing on vaccine availability to be held by the House Committee on Energy and Commerce on Tuesday as the United States crossed the staggering milestone of 500,000 COVID-19 deaths.
The remarks put the United States on track to receive 240 million doses by the end of March, enough to inoculate 130 million Americans, and 700 million doses by mid-year.
AstraZeneca Plc, which is running a US trial for its coronavirus vaccine, believes it can quickly adapt its shot to new variants of the virus in its laboratory, said Ruud Dobber, company president, North America.
A highly contagious COVID-19 variant has become prevalent in South Africa and has turned up in several US states.